Corcept Therapeutics’ oral glucocorticoid receptor antagonist has improved survival outcomes in a late-stage test in patients ...
AstraZeneca has great ambitions for its mid-stage oral cholesterol drug, believing that it could reach peak sales of ...
FDA biologics chief Peter Marks resigns over vaccine dispute with HHS Secretary RFK Jr., causing biotech stocks to drop.
A New York City drug developer led by well-known executives and backed by some of the top names in biotech investing is ...
Phase 2 results on Eli Lilly’s experimental heart disease drug showed it could be dosed far less frequently than competing ...
LifeMine restructures with layoffs; PTC's Translarna is pulled in Europe; Opthea ends AMD trials; Apollomics and LaunXP make ...
Isomorphic Labs, one of the leading AI-driven drug discovery companies within Alphabet, has reeled in $600 million in ...
SV Health Investors, fresh off a $250 million fund for dementia-focused biotechs, has unveiled its latest effort, this time ...
BiomX's BX211 virus therapy shows promise in Phase 2 trial, reducing foot ulcer size in diabetic bone infection patients ...
Vertex halts VX-264 diabetes cell therapy due to poor efficacy in Phase 1/2 study, but continues Phase 3 trial of zimislecel ...
Transcend Therapeutics’ PTSD treatment succeeded in a mid-stage study, propelling the scrappy company of less than 20 people toward a Phase 3 study that could begin at the start of next year.
Welcome back to Endpoints Weekly, where we recap the week’s biggest news from the biopharma industry. Let’s start in DC. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback